Utah

Utah’s policy trajectory has been incremental and institutional. H.B. 167 in 2022 created the evidence-review task force; S.B. 266 in 2024 created a temporary behavioural-health-treatment section in the controlled-substances chapter; the current code reflects a narrowed, still temporary version effective 14 Oct 2025; and H.B. 390 in 2026 added the veterans PTSD clinical-study pathway through Huntsman. This sequence shows clear legislative interest, but it remains tightly tied to medical evidence, institutional actors, and formal research safeguards.###

Practical access, however, remains narrow. No Utah law reviewed here authorises open-ended facilitators, service centres, adult-use possession, or a general state-regulated psilocybin system. The model is best described as a restricted medical–research bridge with heavy dependence on large health systems and future federal developments.###

Utah’s strongest verified research node is Huntsman Mental Health Institute / University of Utah. The 2026 veteran-PTSD statute requires HMHI to run a psychedelic-assisted therapy safety-and-feasibility study for eligible veterans, under an FDA investigational new drug application, DEA Schedule I research registration, IRB approval, detailed safety plans, therapist qualification standards, adverse-event reporting, fidelity monitoring, and a final written report to the Health and Human Services Interim Committee.###

Outside classical psychedelics, HMHI already has a substantial treatment-resistant mood-disorders platform with intravenous ketamine and related treatment-development activity. University materials describe the TRMD clinic as the only Utah clinic offering a full range of certain evidence-based advanced mood-disorder interventions and note its use of clinical trials and large treatment volumes; the KAP clinic, meanwhile, frames itself as both a clinical offering and a data-generating platform.###

Utah’s implementation machinery is unusually explicit for a state that still has no Oregon- or Colorado-style service model. The veteran-study statute sets concrete requirements around IND status, DEA Schedule I registration, IRB approval, study design, informed consent, storage and chain-of-custody controls, emergency response, adverse-event capture, pause/stop rules, therapist qualifications, fidelity monitoring, ethics safeguards, and legislative reporting. That level of implementation detail matters because it shows Utah is building a research-operational scaffold, not a low-regulation access channel.###

For current patient-facing services, implementation remains provider-led and constrained. HMHI’s ketamine pages describe screening, repeated infusion protocols, referral-based entry points, and self-pay elements for KAP. Utah therefore has more operational sophistication than many non-reform states, but that sophistication presently sits inside hospital-style and academic-clinical structures, not an independent psychedelic-services licensing regime.###

The core Utah ecosystem is institutional and centred on the University of Utah / Huntsman Mental Health Institute. Verified components include the Treatment-Resistant Mood Disorders Clinic, intravenous ketamine services, the ketamine-assisted psychotherapy clinic in the HMHI network, and the newly authorised veteran-study platform.###

Utah also has a policy ecosystem that runs through the Legislature, DHHS-linked evidence review, and the Interim Committee reporting structure. That makes the state relevant to researchers, hospital leaders, and investors watching “medicalised bridge” models, even though it still does not offer a broad classical psychedelic access market.###

Over the next 12 to 24 months, Utah’s most important variable is execution at Huntsman. If HMHI secures sufficient appropriations and donations and clears the federal research prerequisites, Utah could become a nationally visible example of a state-authorised, university-run psychedelic study for veterans with treatment-resistant PTSD. If not, the statute still permits a later start once funds become sufficient, so the law creates durable optionality rather than immediate access.###

The other near-term question is whether the temporary behavioural-health-treatment section is used in practice before its 1 Jul 2027 repeal date. The reviewed sources do not verify live non-study psilocybin or MDMA programmes under that section, so This page should keep its language conservative unless a provider, regulator, or legislative report confirms real-world use. Ketamine access is the clearer present-tense story.###